COVID-19
IL-6–based mortality risk model for hospitalized patients with COVID-19

https://doi.org/10.1016/j.jaci.2020.07.009Get rights and content

Background

Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic. Because the severity of the disease is highly variable, predictive models to stratify patients according to their mortality risk are needed.

Objective

Our aim was to develop a model able to predict the risk of fatal outcome in patients with COVID-19 that could be used easily at the time of patients' arrival at the hospital.

Methods

We constructed a prospective cohort with 611 adult patients in whom COVID-19 was diagnosed between March 10 and April 12, 2020, in a tertiary hospital in Madrid, Spain. The analysis included 501 patients who had been discharged or had died by April 20, 2020. The capacity of several biomarkers, measured at the beginning of hospitalization, to predict mortality was assessed individually. Those biomarkers that independently contributed to improve mortality prediction were included in a multivariable risk model.

Results

High IL-6 level, C-reactive protein level, lactate dehydrogenase (LDH) level, ferritin level, d-dimer level, neutrophil count, and neutrophil-to-lymphocyte ratio were all predictive of mortality (area under the curve >0.70), as were low albumin level, lymphocyte count, monocyte count, and ratio of peripheral blood oxygen saturation to fraction of inspired oxygen (SpO2/FiO2). A multivariable mortality risk model including the SpO2/FiO2 ratio, neutrophil-to-lymphocyte ratio, LDH level, IL-6 level, and age was developed and showed high accuracy for the prediction of fatal outcome (area under the curve 0.94). The optimal cutoff reliably classified patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with 0.88 sensitivity and 0.89 specificity.

Conclusion

This mortality risk model allows early risk stratification of hospitalized patients with COVID-19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to guide clinical decision making.

Key words

COVID-19
IL-6
mortality risk
predictive model

Abbreviations used

ALT
Alanine transaminase
ARDS
Acute respiratory distress syndrome
AST
Aspartate transaminase
AUROCC
Area under the receiver operating characteristic curve
COVID-19
Coronavirus disease 2019
CRP
C-reactive protein
ICU
Intensive care unit
LDH
Lactate dehydrogenase
N/L
Neutrophil-to-lymphocyte
PPV
Positive predictive value
ROC
Receiver operating characteristic
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SOFA
Sequential organ failure assessment
SpO2/FiO2
Peripheral blood oxygen saturation–to–fraction of inspired oxygen

Cited by (0)

Supported by the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (COVID-19 research call COV20/00181), and cofinanced by the European Development Regional Fund A Way to Achieve Europe, Operative Program Intelligent Growth 2014-2020. R.L.G. and O.C.M. each hold a Rio Hortega research contract (CM19/00120 and CM19/00092, respectively). P.T. holds a Juan Rodes research contract (JR19/00049), and M.F.R. holds a Miguel Servet research contract (CP18/00073), all from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation. The funder of this study had no role in the study design, data collection, data analysis, interpretation of the data, or writing of the report. R.L.G. had full access to all the data and final responsibility to submit for publication. A.U.R. also had access to all the raw data.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

View Abstract